FRENCH BIOTECH FIRM, WYETH TO DEVELOP HEMOPHILIA DRUGS

Nautilus Biotech, based in France, has signed a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for hemophilia B with Wyeth Pharmaceuticals. These extended half-life proteins will be designed to enhance patient convenience, as they will reduce the number and frequency of treatments needed, according to Nautilus. Wyeth currently markets the only recombinant Factor IX product, BeneFIX.

As part of the agreement, Nautilus will apply its proprietary technology to improve the duration of action of recombinant hemophilia B therapy. The company's technology makes minimal and specific changes to the amino acid sequence in order to slow the breakdown of the protein in the body.

Under the terms of this agreement, Wyeth will develop, manufacture and market successful products derived from the collaborative research. Nautilus will receive an upfront payment, R&D fees, milestone payments associated with development, regulatory filings and approvals, and royalty payments based on net sales.

"Nautilus Biotech has a unique technology for improving protein medicines and Wyeth has an impressive track record as a pioneer in developing state-of-the art hemophilia therapies," Manuel Vega, CEO of Nautilus Biotech, said.